计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B129905-10mg |
10mg |
现货 ![]() |
| |
| B129905-50mg |
50mg |
现货 ![]() |
| |
| B129905-100mg |
100mg |
现货 ![]() |
| |
| B129905-250mg |
250mg |
期货 ![]() |
| |
| B129905-1g |
1g |
期货 ![]() |
|
| 别名 | 伯舒替尼 |
|---|---|
| 英文别名 | SKI-606 | WAY-173606 | Bosutinib,SKI-606 | BSPBio_001023 | NCGC00241107-03 | NSC799367 | NSC-799367 | 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile | 5018V4AEZ0 | DB06616 | SK 606 | 2-[4-(2 |
| 规格或纯度 | Moligand™, ≥99% |
| 英文名称 | Bosutinib (SKI-606) |
| 生化机理 | Abl和Src激酶的双重抑制剂(在酶法测定中,Src的IC50 = 1.2 nM)。对慢性骨髓性白血病(CML)细胞显示抗增殖活性,并降低乳腺癌细胞系的运动性和侵袭性。在不依赖于锚定的Src转化的大鼠成纤维细胞(IC50 = 100 nM)中也表现出有效的抗增殖活性。与非Src家族激酶(例如生长因子受体酪氨酸激酶)相比,显示Src的选择性。 |
| 运输条件 | 常规运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 酪氨酸蛋白激酶 Lyn 抑制剂 |
| 产品介绍 |
Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration.A c-Abl, Src-Abl, and Bcr-Abl inhibitor Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration. |
| 纯度 | ≥99% |
| ALogP | 5.4 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504763636 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile |
| INCHI | 1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31) |
| InChi Key | UBPYILGKFZZVDX-UHFFFAOYSA-N |
| Smiles | CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
| Isomeric SMILES | CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC |
| 分子量 | 530.45 |
| Reaxy-Rn | 9100307 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=9100307&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 53.05, 最高浓度(mM): 100;溶于ethanol, 最高浓度 (mg/mL): 13.26, 最高浓度(mM): 25 |
|---|---|
| 分子量 | 530.400 g/mol |
| XLogP3 | 5.400 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 9 |
| 精确质量Exact Mass | 529.165 Da |
| 单同位素质量Monoisotopic Mass | 529.165 Da |
| 拓扑极表面积Topological Polar Surface Area | 82.900 Ų |
| 重原子数Heavy Atom Count | 36 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 734.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | Warning |
| WGK Germany | 3 |
| 1. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V et al.. (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.. Cancer Res, 66 (23): (11314-22). [PMID:17114238] |
| 2. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M et al.. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.. Leukemia, 23 (3): (477-85). [PMID:19039322] |
| 3. Ozanne J, Prescott AR, Clark K. (2015) The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.. Biochem J, 465 (2): (271-9). [PMID:25351958] |